0001193125-26-211867
SEC filingLeonaBio reported Q1 2026 financial results, highlighting progress in its Phase 3 lasofoxifene trial and Phase 2 ATH-1105 study, with net loss widening to $32.9 million.
LeonaBio's Q1 2026 results reflect a period of significant investment in its lead pipeline, particularly the Phase 3 ELAINE-3 trial for lasofoxifene in ESR1-mutated metastatic breast cancer. R&D expenses more than doubled to $10.3 million from $4.3 million in the prior year quarter, driving the net loss to $32.9 million ($1.73 per share) compared to $9.1 million ($2.34 per share) in Q1 2025. The company ended the quarter with $67.7 million in cash, down from $88.3 million at year-end 2025, reflecting $20.9 million in operating cash burn. Management highlighted the December 2025 $90 million financing and potential $146 million from warrant exercises as providing runway through key milestones. Operationally, the company expects to complete enrollment of the ELAINE-3 trial in Q4 2026 with topline data in H2 2027, and plans to initiate a Phase 2 proof-of-concept study for ATH-1105 in ALS in H2 2026. Three new board members were appointed effective May 5, 2026, bringing expertise in finance, biotech leadership, and operations. The press release also noted a virtual KOL event discussing lasofoxifene's potential. No forward guidance was provided beyond clinical timelines.